Oral Carvedilol in Escalating Doses in the Acute Treatment of Atrial Fibrillation

Oral carvedilol administered in escalating doses in patients with atrial fibrillation among patients with AF with fast ventricular rate.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Atrial Fibrillation Arrhythmias, Cardiac Cardiovascular Diseases Heart Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

About this study

Patients with AF with FVR of any etiology were evaluated and given escalating doses of oral carvedilol in doses - 3.125mg OD, then 3.125 bid, then 6.25mg bid, then 12.5mg bid. The ECG was recorded regularly and analysed for rate reduction or control.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

AF with fast ventricular rate

Exclusion criteria

Treatment and study plan

oral carvedilol

Drug

oral carvedilol in escalating doses for reducing ventricular rate in AF patients

Other names: oral carvedilol in esclating doses

Primary outcomes

reduction in ventricular rate in AF patients

Time frame: 24 hours

reduction in ventricular rate in patients with AF and fast ventricular rate.

Sponsors and collaborators

Lead sponsor

Andhra Medical College

Other Gov

Registry information

Important dates

Study start: 2000
Primary completion: 2002
Study completion: 2002
First posted: Jul 14, 2016
Registry last updated: Jul 14, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed